The RS assay has been clinically validated and the test is performed at the central clinical reference laboratory of Genomic Heath, Inc. EndoPredict (EP) and EPclin, which is a combination of EP with tumour size and nodal status, predict distant recurrence and they can be applied to ER+/Her2- breast cancers [12]. This evidence concerns the gene ESR1 and breast cancer.